Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis

Trial Profile

A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telazorlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals S.A.
  • Most Recent Events

    • 01 Mar 2019 According to a Glenmark Pharmaceuticals media release, a new post hoc analysis data from this study assessing the activity of GBR 830 in patients with intrinsic and extrinsic atopic dermatitis subtypes, and for subjects with elevated IgE levels at baseline, were presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
    • 01 Mar 2019 Results of new post hoc analysis from this study presented in a Glenmark Pharmaceuticals media release.
    • 25 Feb 2019 Results of a post-hoc analysis assessing the activity of GBR 830 in patients with Intrinsic and Extrinsic Atopic Dermatitis, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top